Pharvaris N.V. Ordinary Shares (PHVS) Dividend History

Pharvaris N.V. is a biopharmaceutical company focused on developing therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling episodes. The company's approach involves targeting the kallikrein-kinin system to develop innovative treatments that address the underlying causes of HAE. Headquartered in the Netherlands, Pharvaris aims to improve the quality of life for patients through its pipeline of novel oral and injectable therapies.

Website:

Dividend History

Pharvaris N.V. Ordinary Shares currently does not pay dividends

Company News

  • Pharvaris Announces Annual Meeting of Shareholders

    ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CEST (9:00 a.m. EDT).

    GlobeNewswire Inc.
  • Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

    ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

    GlobeNewswire Inc.
  • Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

    ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows:

    GlobeNewswire Inc.
  • Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

    ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

    GlobeNewswire Inc.
  • Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 20:03:36 UTC